CDK1 and non-small cell lung carcinoma: Purvalanol A, a Cdc2 / Cdk1 inhibitor, potentiates the cytotoxicity of Paclitaxel on non-small cell lung cancer cells in vitro by targeting Op18/stathmin [48].